Trial Profile
To describe predictors of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics
- 24 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management